BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | Sep 12, 2019
Distillery Techniques

Beam co-founder describes base editors with reduced RNA editing

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Gene therapy Beam Therapeutics co-founder J. Keith Joung and colleagues described cytosine and adenine base editors that could reduce off-target RNA editing compared with prior versions of the technologies. An...
BioCentury | Sep 4, 2019
Preclinical News

Preclinical Quick Takes: NIH's clinical trial practices in preclinical studies, plus Kancera and optimized base editors

NIH to fund preclinical studies implementing clinical practices for stroke NIH plans to fund a preclinical trial platform that uses clinical research practices to study therapies for stroke. NIH's NINDS will invest $4 million over...
BioCentury | Jun 20, 2019
Distillery Techniques

Clinically relevant genomic alterations in metastatic breast cancers

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Genomic analyses have identified sets of genetic alterations that could help diagnose hormone receptor (HR)-positive, HER2-negative metastatic breast cancer subtypes and predict associated prognoses. An analysis comparing...
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
BioCentury | Aug 31, 2018
Financial News

ApoGen expands series A to $11M

Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Mar 30, 2017
Emerging Company Profile

Resisting resistance

While many companies are attempting to counteract mutations in cancer that result in resistance, ApoGen Biotechnologies Inc. is instead targeting a mechanism that causes resistance mutations to develop. The approach could prolong responses to cancer...
BioCentury | Mar 14, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts A CRISPR-based gene editing method of generating point mutations could be used to create animal models of genetic diseases. The method introduced cytosine-to-thymine (C-to-T) mutations into the DNA of mouse embryos...
Items per page:
1 - 10 of 19